These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 33771086)

  • 1. Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
    Moum KM; Moum B; Opheim R
    Scand J Gastroenterol; 2021 May; 56(5):545-551. PubMed ID: 33771086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
    Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
    Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
    Arrigo S; Alvisi P; Banzato C; Bramuzzo M; Celano R; Civitelli F; D'Arcangelo G; Dilillo A; Dipasquale V; Felici E; Fuoti M; Gatti S; Knafelz D; Lionetti P; Mario F; Marseglia A; Martelossi S; Moretti C; Norsa L; Panceri R; Renzo S; Romano C; Romeo E; Strisciuglio C; Martinelli M
    Dig Liver Dis; 2021 Mar; 53(3):283-288. PubMed ID: 33388247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
    Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic.
    Iborra I; Puig M; Marín L; Calafat M; Cañete F; Quiñones C; González-González L; Cardona G; Mañosa M; Domènech E
    Dig Dis Sci; 2021 Dec; 66(12):4191-4196. PubMed ID: 33469807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 in IBD: The experience of a single tertiary IBD center.
    Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
    Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
    Brenner EJ; Pigneur B; Focht G; Zhang X; Ungaro RC; Colombel JF; Turner D; Kappelman MD; Ruemmele FM
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):394-396.e5. PubMed ID: 33059040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review on medical management of inflammatory bowel disease during the coronavirus disease 2019 pandemic.
    Chela H; Pasha SB; Wan XF; Ghouri YA
    J Gastroenterol Hepatol; 2021 Apr; 36(4):918-926. PubMed ID: 32876952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
    Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Efficiency, and Acceptability of Telemedicine for Inflammatory Bowel Disease Patients' Follow-Up Care during the COVID-19 Pandemic.
    Ramos L; Reygosa C; Carrillo-Palau M; Alonso-Abreu I; González-Mendez Y; de la Barreda R; Amaral C; Hernández A; Benítez-Zafra F; Hernandez-Guerra M
    Dig Dis; 2023; 41(4):574-580. PubMed ID: 36716727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of restrictions on psychological outcomes in patients with inflammatory bowel disease on biological treatment during the coronavirus pandemic in Norway.
    Opheim R; Moum KM; Småstuen MC; Moum B
    Qual Life Res; 2023 Mar; 32(3):691-699. PubMed ID: 36125603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
    Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
    Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic.
    Goodsall TM; Han S; Bryant RV
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1550-1555. PubMed ID: 33063927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Hansen R; Meade S; Beattie RM; Auth MK; Croft N; Davies P; Devadason D; Doherty C; Epstein J; Howarth L; Kiparissi F; Muhammed R; Shivamurthy V; Spray C; Stanton MP; Torrente F; Urs A; Wilson D; Irving PM; Samaan M; Kammermeier J
    Gut; 2021 Jun; 70(6):1044-1052. PubMed ID: 32873696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.
    Kante B; Vuyyuru SK; Gupta R; Dwivedi T; Kumar P; Mundhra S; Golla R; Virmani S; Verma M; Makharia G; Ahuja V; Kedia S
    Indian J Gastroenterol; 2023 Feb; 42(1):70-78. PubMed ID: 36738383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study.
    Lindhagen S; Karling P
    Scand J Gastroenterol; 2022 Feb; 57(2):169-174. PubMed ID: 34699290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease.
    Moser G; Tillinger W; Sachs G; Genser D; Maier-Dobersberger T; Spiess K; Wyatt J; Vogelsang H; Lochs H; Gangl A
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):853-8. PubMed ID: 8574717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.